H.C. Wainwright analyst Ed Arce maintained a Hold rating on Arcturus Therapeutics (ARCT – Research Report) today and set a price target of $50.00. The company’s shares closed last Wednesday at $31.85, close to its 52-week low of $24.87.
According to TipRanks.com, Arce is a 4-star analyst with an average return of 13.6% and a 35.0% success rate. Arce covers the Healthcare sector, focusing on stocks such as Entasis Therapeutics Holdings, Madrigal Pharmaceuticals, and Aurinia Pharmaceuticals.
Arcturus Therapeutics has an analyst consensus of Hold, with a price target consensus of $38.17.
The company has a one-year high of $129.71 and a one-year low of $24.87. Currently, Arcturus Therapeutics has an average volume of 499.2K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Arcturus Therapeutics Holdings, Inc. engages in the development of RNA therapeutics for treatment. It focuses on liver and respiratory diseases. Its pipeline include LUNAR-OTC, and LUNAR CF. The company was founded in 2013 and is headquartered in San Diego, CA.